Ukrainian Pharma: challenges and opportunities Pharmaceutical Industry Review, special issue, December 2022
Development under the fire: the war did not break down the leader of the pharma industry of Ukraine – on the contrary strengthened its endurance
During large-scale war pharmaceutical company Farmak experiences both USD 50 M losses as well as complete renewal and even extension of its manufacturing capacities in Ukraine. Recently the company announced construction of a new facility in south-west Europe. War challenges did not stop leader of Ukrainian pharma – on the contrary they gave impulse for new co-operation prospective with international partners.
S
ince the first days after international intelligence informed about possible
russian hostile attack of sovereign state of Ukraine the company Farmak started to prepare itself for different scenarios: purchased raw materials for medicines production and diesel electricity generation machines. Protection of employees was the priority task for the company – thus first of all the shelters were checked. The company invested in shelters modernization when it became clear that they can’t be used. At the same time the training was provided to employees in order to enhance understanding of what shall be dome under any circumstances and first medical aid basics. Anyhow no one could imagine all horrors of war even provided the most responsible preparations of Ukrainian business. Farmak had to stop medicines manufacturing during the first days of large scale war after bombarding attacks of Kyiv. One of the main reasons was safety of employees and assets of the company – better to say it was impossible to ensure them. The next blow was destruction by the enemy of the warehouse near Kyiv with finished dosage forms
48 BACK TO CONTENTS
and primary packaging. The company lost USD 50 M, but did not give up. Farmak’s CEO Volodymyr Kostyuk mentioned that at that time he received numerous phone calls from government officials, military units, hospitals and volunteers who were asking for supply of necessary medicines. On the other hand company’s employees also were eager to work despite all existing risks. During that time Ukraine faced unprecedented disruption of medicines distribution system. Up to 90% of pharmacies were closed during first weeks of war. At the moment about 900 units of healthcare system are damaged. Besides the country experienced real problems with import of finished dosage forms and raw materials (API and primary packaging) because transportation by air and by sea was not available. Some warehouses of distributors were closed. This was the reason for Farmak to resume manufacturing activities in full despite all difficulties. During several months after large scale military invasion the healthcare system managed to overcome majority of the problems and to prevent deficit of medicines
INFORMATION ON THE COMPANY
Farmak is the leader in the field of medicines manufacturing in Ukraine, largest pharmaceutical company and leading exporter of nationally manufactured products to the markets of more than 50 countries. The company has more than 450 medicines in its portfolio. There are 5 international representative offices in Uzbekistan, Kazakhstan, Kyrgyzstan, Poland and Vietnam, as well as office in UAE. Farmak has manufacturing facilities in Kyiv and a facility for API production in Shostka, Sumy region. Company also has modern R&D Laboratory and Technological Complex for development of new and improvement of existing medicines manufacturing technologies. Both production facilities and R&D Laboratory and Technological Complex have international certification and correspond to requirements of European GMP standards.
www.promoboz.com
www.promoboz.com |
www.cphem.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
